Menten AI vs GE HealthCare
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 AI cyclic peptide drug discovery with Bristol Myers Squibb collaboration May 2024; $4.15M Khosla/Uncork/Feld-backed using ML+quantum computing for peptide optimization competing with Relay Therapeutics for pharma licensing.
About
Menten AI is a San Francisco-based AI drug discovery company — backed by Y Combinator (W20) with $4.15 million in total funding from Y Combinator, Khosla Ventures, Uncork Capital, Feld Ventures, Mana Ventures, Quain Investments, Society Health, and Volpini Ventures — developing peptide and protein therapeutics using machine learning and quantum computing to design novel cyclic peptide drug candidates for pharmaceutical licensing partnerships, completing a research collaboration with Bristol Myers Squibb in May 2024. Founded in 2018, Menten AI applies advanced AI algorithms for cyclic peptide optimization and protein structure design with a business model centered on licensing proprietary algorithms and drug candidates to pharma partners rather than developing therapeutics through full clinical development.
Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.
About
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.